Q3 2025 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2025-11-14 · accession 0001583977-25-000011
$1.45B
Reported value
36
Positions
2025-09-30
Period end
The Brief · Cormorant Asset Management, LP · Q3 2025
AI · grounded in 13F
Cormorant Asset Management, LP established a new position in BBOT valued at $207.03M. The fund also initiated new stakes in ABVX for $165.56M and EYPT for $118.55M. Additional new positions include RAPP, BBIO, and EWTX. The fund ended the period with 36 positions and total AUM of $1.45B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $207.0M | 14.3% | 17,878,594 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $165.6M | 11.4% | 1,950,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $118.5M | 8.18% | 8,325,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $94.8M | 6.54% | 3,192,521 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $72.7M | 5.02% | 1,400,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $65.0M | 4.49% | 4,010,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $64.3M | 4.43% | 1,059,331 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $63.6M | 4.39% | 775,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $61.9M | 4.27% | 430,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $61.9M | 4.27% | 2,175,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $53.0M | 3.66% | 1,000,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $46.7M | 3.22% | 1,925,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $34.0M | 2.35% | 1,363,200 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $30.0M | 2.07% | 2,375,000 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $27.4M | 1.89% | 1,916,439 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $25.2M | 1.74% | 625,000 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $22.3M | 1.54% | 465,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $21.4M | 1.48% | 1,225,000 | Common | SOLE |
| 59267L107 | — | METSERA INC | $20.9M | 1.44% | 400,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $20.8M | 1.43% | 850,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $17.8M | 1.23% | 300,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $16.7M | 1.15% | 400,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $15.9M | 1.10% | 2,323,595 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $14.6M | 1.01% | 775,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $14.3M | 0.99% | 1,994,173 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $13.1M | 0.90% | 300,000 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $12.6M | 0.87% | 2,140,605 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $12.1M | 0.84% | 100,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $11.7M | 0.81% | 5,000,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $10.3M | 0.71% | 533,340 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $8.6M | 0.59% | 2,147,396 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $7.2M | 0.50% | 3,570,872 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $6.8M | 0.47% | 500,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $6.3M | 0.43% | 175,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $4.1M | 0.28% | 200,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $150,100 | 0.01% | 10,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.